血小板生成素受体激动剂在血小板减少性疾病中应用的研究进展

Research progress on applications of thrombopoietin receptor agonist in thrombocytopenic diseases

血小板减少性疾病是常见的血液系统疾病，病因繁多，多见于原发免疫性血小板减少症（ITP）、骨髓衰竭性疾病、恶性血液病、慢性肝脏疾病，以及化疗引起的血小板减少症。目前，血小板生成素受体激动剂（TPORA）在各种血小板减少性疾病治疗中具有重要意义，可有效提高患者血小板计数，为血小板减少性疾病患者提供新的治疗方法。本文就TPORA在血小板减少性疾病中的临床应用和治疗安全性方面的研究进展进行综述。

Thrombocytopenic diseases are common diseases of the blood system diseases, which have various pathopoiesis factors. This clinical disorder can be found in the following diseases： primary immune thrombocytopenia （ITP）, bone marrow failure diseases, hematologic malignancies, chronic liver disease and thromboeytopenia caused by chemotherapy and so on. Currently thrombopoietin receptor agonists （TPRA） play a significant role in improving the count of platelets effectively. This article reviews the research progress on clinical application and therapeutic safety of TPORA in thrombocytopenic diseases.